

1 Supporting information

2 **S1 Appendix. Association between prenatal treatment and newborn characteristics including the**
 3 **“uncertain prenatal treatment group” (7-27 days of treatment) in the analysis within the**
 4 **prenatal treatment group.**

	Prenatal treatment				Univariate analysis		Multivariate analysis	
	No (n=19)		Yes (n=37)		p	OR (95% CI)	p	OR (95% CI)
	n	%	n	%				
Confirmed maternal infection								
1 st trimester	3/15	15.78	2/36	5.55				
2 nd trimester	1/15	5.26	10/36	27.02				
3 rd trimester	11/15	57.89	24/36	64.86	0.16			
Prematurity	5/19	26.32	3/37	8.11	0.08			
Symptomatic CT (all)	11/19	57.89	10/37	27.03	0.03	3.71 (1.12–12.21)	0.09	3.11 (0.80–12.08)
Ocular CT	5/19	26.32	4/37	10.81	0.15		0.19	
CNS CT	9/19	47.37	6/37	16.22	0.01	4.65 (1.28–16.78)	0.17	
Generalized CT	3/19	15.78	1/37	2.70	0.11		0.21	
New IRC (all)	6/19	31.58	2/37	5.40	0.02	8.07 (1.38–47.02)	0.01	18.55 (1.78–192.43)
New ocular IRC	4/19	21.05	1/37	2.70	0.05	9.60 (0.93–98.13)	0.04	16.85 (1.14–248.16)
New CNS IRC	3/19	15.79	1/37	2.70	0.11		0.08	11.92 (0.70–200.46)

5 *CI = confidence interval; CNS = central nervous system; CT = congenital toxoplasmosis; IRC =*
 6 *infection-related complications; OR = odds ratio.*